^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ETBX-051
i
Other names: ETBX-051, ETBX 051, Ad5 brachyury vaccine, adenoviral brachyury vaccine, Ad5 [E1-, E2b-]-brachyury
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ImmunityBio
Drug class:
Immunostimulant, Brachyury inhibitor
Related drugs:
7ms
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov)
P1/2, N=79, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 overexpression • HER-2 amplification • PGR expression
|
Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI 4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
11ms
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection (clinicaltrials.gov)
P1/2, N=21, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Trial completion • Combination therapy
|
CDKN2A negative
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061
2years
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov)
P1/2, N=79, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Jan 2020 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2022
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 overexpression • HER-2 amplification • PGR expression
|
Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI 4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
Share via
